ASTER is a concept for the infusion of radiopharmaceuticals and will be available on the market starting in 2023.
In the last few years, the development of effective radiometabolic therapies has led to the emergence of the Theragnostic approach as a specific application of nuclear medicine.
Very quickly, from being an experimental therapy, Theragnostics is gradually becoming a treatment protocol increasingly used by nuclear medicine departments. And with the increase in treatments, the critical issues associated with a completely manual handling of radiopharmaceuticals and administration to patients could result in complications for the entire department.
ASTER was created to respond to these critical issues and to support those nuclear medicine departments wishing to increase their Theragnostic activity or start new treatments with radiometabolic therapies.
The completely manual administration of radiopharmaceuticals, even with moderate activity such as those used in Theragnostics, always involves numerous critical issues. From the exposure to which operators and patients are potentially subjected, to the possibility of department contamination due to accidental radiopharmaceutical spills.
ASTER is a system composed of 5 elements, each of which is designed to simplify and make safer the entire process for administering radiometabolic therapies.